



**.rise to.
immunize**

Measure Specifications

Version 1.2 | November 22, 2021



Advancing High Performance Health

TABLE OF CONTENTS

| | | |
|------------|--|-----------|
| 1 | Purpose | 3 |
| 2 | Measures Overview | 3 |
| 2.1 | Definitions | 3 |
| 2.1.1 | Flu Season/Measurement Year | 3 |
| 2.1.2 | Cumulative Quarters | 4 |
| 2.1.3 | Measurement Period & Reporting Quarter | 4 |
| 2.1.4 | Fig. 1: Cumulative Quarters | 4 |
| 2.1.5 | Active Patient Lookback Period | 4 |
| 2.1.6 | Fig. 2: Active Patient Lookback | 5 |
| 2.1.7 | Vaccination Documentation and Administration | 5 |
| 2.2 | List of Measures | 5 |
| 2.2.1 | Basic Track | 5 |
| 2.2.2 | Core Track | 6 |
| 2.3 | Reporting | 6 |
| 2.3.1 | Data Sources | 6 |
| 2.3.2 | Process | 6 |
| 3 | Measure Specifications | 10 |
| 3.1 | Active Patient Population | 10 |
| 3.1.1 | Defining the Active Patient Population | 11 |
| 3.1.2 | Date of Birth (DOB) Range to Establish Active Patient Population | 11 |
| 3.2 | Measure 1 (Influenza) | 13 |
| 3.2.1 | Denominator | 13 |
| 3.2.2 | Numerator | 13 |
| 3.2.3 | Measure 1 (Influenza) Flowchart | 14 |
| 3.3 | Measures 2-4 Numerator Parts | 14 |
| 3.4 | Measure 2 (Pneumococcal) | 15 |
| 3.4.1 | Denominator | 15 |
| 3.4.2 | Numerator Part A | 15 |
| 3.4.3 | Numerator Part B | 15 |
| 3.4.4 | Measure 2 (Pneumococcal) Flowchart | 15 |
| 3.5 | Measure 3 (Td/Tdap) | 16 |
| 3.5.1 | Denominator | 16 |
| 3.5.2 | Numerator Part A | 16 |
| 3.5.3 | Numerator Part B | 16 |
| 3.5.4 | Measure 3 (Td/Tdap) Flowchart | 16 |
| 3.6 | Measure 4 (Zoster) | 17 |
| 3.6.1 | Denominator | 17 |
| 3.6.2 | Numerator Part A | 17 |
| 3.6.3 | Numerator Part B | 17 |
| 3.6.4 | Measure 4 (Zoster) Flowchart | 17 |

3.7 Measure 5 (Bundle).....18
3.7.1 Denominator18
3.7.2 Numerator18
3.7.3 Measure 5 (Bundle) Flowchart18

4 Change Log 19

5 Quick Links & Contact Information..... 19

1 PURPOSE

The purpose of this document is to provide guidance to participating health care organizations (HCOs) on measures data to be submitted for AMGA Foundation's national adult immunization campaign, Rise to Immunize™.

The campaign focuses on closing care gaps for the influenza; pneumococcal; tetanus, diphtheria, and pertussis (Td/Tdap); and zoster vaccinations among eligible adults in the US.

Measurement is essential to any improvement process. That is why measurement is a cornerstone of AMGA learning collaboratives and campaigns. Measurement is necessary not only to gauge impact, but also to serve as a vital tool for AMGA members to create change. We recommend using measure data as part of a feedback loop to determine whether interventions are working. Data should be shared with all participating clinic sites and providers. Comparing data at this level presents a learning opportunity to understand how differing processes and workflows may be contributing to improvement. Campaign participants are required to submit measure data quarterly, but AMGA strongly recommends that participating HCOs review data on their own at least monthly.

2 MEASURES OVERVIEW

These measures were developed by the Rise to Immunize™ National Advisory Committee (NAC) (see [Contact Information](#) for a list of advisors) and are based on the HEDIS® Adult Immunization Status (AIS-E) measure. HEDIS® value sets are provided in an accompanying Excel workbook (HEDIS Value Sets for Rise Measures.xlsx). We greatly appreciate NCQA's generosity in granting permission to use these value sets for Rise to Immunize™. While the measures for the Rise to Immunize™ campaign are based on the HEDIS® Adult Immunization Status measures and value sets, they have not been validated by NCQA.

Rise to Immunize™ offers two data reporting tracks—[Basic](#) and [Core](#)—to fit the capabilities and interests of each AMGA member. The Basic track includes only the influenza and pneumococcal measures (1 & 2). The Core track adds the zoster, Td/Tdap, and immunization bundle measures (3, 4, & 5) in addition to the influenza and pneumococcal measures.

Measures are submitted for the purpose of monitoring progress within and across organizations; they are not intended to replace clinical guidelines. Clinicians should continue to follow evidence-based practices, guidelines, and clinical judgement when administering immunizations.

2.1 DEFINITIONS

2.1.1 Flu Season/Measurement Year

Flu Seasons span from the beginning of Q3 to the end of Q2 (e.g., July 1, 2021—June 30, 2022). **In this document, the Flu Season is equivalent to the Measurement Year (MY).** For consistency, all measures—not just influenza—are reported using the MY time frame. Measurement Years are named after the year in which they began (e.g., the MY of July 1, 2021—June 30, 2022, is named Measurement Year 2021).

2.1.2 Cumulative Quarters

All measures will be reported as cumulative quarters. Beginning with Q3 (the start of the MY), totals for each measure will be **added** to the previous quarter’s totals, resetting on the next Q3 (see [Fig. 1](#)). A full set of cumulative quarters spans one full MY (Q3 to Q2 of the following calendar year).

2.1.3 Measurement Period & Reporting Quarter

The Measurement Period (MP) is defined as all cumulative quarters reported to date within a given MY (see [Fig. 1](#)). The Reporting Quarter (RQ) refers to the last (i.e., the most recent) quarter of data in the MP. **The RQ term is mostly used for naming purposes.** An MP will be referred to by its unique RQ (see Tables [1](#) & [2](#)).

2.1.4 Fig. 1: Cumulative Quarters

| Reporting Quarter (RQ) | Quarters Included in Measurement Period (MP) | # of Quarters Reported |
|------------------------|--|------------------------|
| Q3 = | | 1 |
| Q4 = | | 2 |
| Q1 = | | 3 |
| Q2 = | | 4 |

2.1.5 Active Patient Lookback Period

To determine the Active Patient Population (defined in [Section 3.1](#)), HCOs will identify patients with specified activity in the Active Patient Lookback Period (APL) (see [Fig 2](#)). The APL begins 15 months prior to Q3 (the beginning of each MY) and runs through the end of the current RQ. The APL resets at the beginning of each MY (see Tables [1](#) & [2](#)).

2.1.6 Fig. 2: Active Patient Lookback

| Reporting Quarter (RQ) | Quarters Included in Active Patient Lookback (APL) | # of Months in APL |
|------------------------|--|--------------------|
| Q3 | | 18 |
| Q4 | | 21 |
| Q1 | | 24 |
| Q2 | | 27 |

2.1.7 Vaccination Documentation and Administration

HCOs should ultimately use their own definitions and policies of vaccination documentation. It is recommended to accept credible patient self-reports of *influenza* vaccinations. For *pneumococcal*, *zoster*, and *Td/Tdap* vaccinations, it is recommended that HCOs require documentation stating that the vaccination was administered.

An accompanying Excel workbook contains relevant value sets from the HEDIS® Adult Immunization Status measure (HEDIS Value Sets for Rize Measures.xlsx). HCOs may use these value sets to aid in the identification of vaccination procedures.

2.2 LIST OF MEASURES

2.2.1 Basic Track

- **Measure 1 (Influenza):** Proportion of eligible patients who received an influenza vaccination any time during the current flu season, i.e., the Measurement Year.
- **Measure 2 (Pneumococcal):** Proportion of eligible patients who were administered a pneumococcal vaccine during the Measurement Year or are documented as up to date on their pneumococcal vaccination.

2.2.2 Core Track

In addition to Measures 1 & 2 (above):

- **Measure 3 (Td/Tdap):** Proportion of eligible patients who were administered a Td or Tdap vaccine during the Measurement Year or are documented as up to date on their Td or Tdap vaccination.
- **Measure 4 (Zoster):** Proportion of eligible patients who completed the zoster vaccination series during the Measurement Year or are documented as up to date on their zoster vaccination.
- **Measure 5 (Bundle):** Proportion of eligible patients who are up to date on all four required vaccinations (influenza, pneumococcal, zoster, Td/Tdap).

2.3 REPORTING

Population-level numerators and denominators for each measure will be reported for active patients (see [Section 3.1](#)) who meet each specific vaccination numerator and denominator requirement. If HCOs choose the Basic track, they will only report numerators and denominators for Measures 1 & 2. If HCOs choose the Core track, they will report all Measures (1 through 5).

2.3.1 Data Sources

The data elements can be derived from medical and pharmacy claims and records, (electronic) practice management systems (PM or EPM), electronic health record systems (EHR), disease registries, population health software, local/state/regional vaccine registries, other health records, etc. These data could have been recorded or collected directly at point-of-care, or they could have originated and been transmitted from another data source.

2.3.2 Process

Data will be submitted **quarterly**. Reports are due approximately two weeks after the end of each RQ.

An excel reporting template along with detailed instructions regarding data submission will be provided to participating HCOs prior to the baseline reporting deadline. HCOs must submit data by attaching the reporting template (populated with aggregate numerator parts and denominators for each measure) to DataForRize@amga.org, a secure data repository that enables automatic parsing and consistency checking for submitted files. No patient-level data will be reported or submitted.

The excel reporting template will provide a cumulative record of the HCOs' reported measures data so the organization can evaluate the consistency of their data from quarter to quarter. This can also be used to track progress, although we recommend that participants track their data more frequently, e.g., monthly. Following each submission deadline, AMGA will provide blinded comparative benchmarking reports across all organizations participating in the campaign.

Table 1: Baseline Reporting Time Periods and Due Date

| Flu Season (Measurement Year) ¹ | Reporting Quarter ² | Active Patient Lookback Period | # of APL Months Included | Measurement Period (Cumulative Quarters) | # of MP Quarters Included | Report Due Date |
|--|--------------------------------|---|--------------------------|--|---------------------------|-----------------|
| Pre-COVID 2019 | Q3 2019 | 4/1/2018–9/30/2019 Q2 2018–Q3 2019 | 18 | 7/1/2019–9/30/2019 Q3 2019 | 1 | Feb 15, 2022 |
| | Q4 2019 | 4/1/2018–12/31/2019 Q2 2018–Q4 2019 | 21 | 7/1/2019– 12/31/2019 Q3 2019–Q4 2019 | 2 | |
| | Q1 2020 | 4/1/2018–3/31/2020 Q2 2018–Q1 2020 | 24 | 7/1/2019– 3/31/2020 Q3 2019 – Q1 2020 | 3 | |
| | Q2 2020 | 4/1/2018–6/30/2020 Q2 2018–Q2 2020 | 27 | 7/1/2019– 6/30/2020 Q3 2019 – Q2 2020 | 4 | |
| Intra-COVID 2020 | Q3 2020 | 4/1/2019–9/30/2020 Q2 2019 - Q3 2020 | 18 | 7/1/2020–9/30/2020 Q3 2020 | 1 | |
| | Q4 2020 | 4/1/2019–12/31/2020 Q2 2019–Q4 2020 | 21 | 7/1/2020–12/31/2020 Q3 2020–Q4 2020 | 2 | |
| | Q1 2021 | 4/1/2019–3/31/2021 Q2 2019–Q1 2021 | 24 | 7/1/2020–3/31/2021 Q3 2020–Q1 2021 | 3 | |
| | Q2 2021 | 4/1/2019–6/30/2021 Q2 2019–Q2 2021 | 27 | 7/1/2020–6/30/2021 Q3 2020–Q2 2021 | 4 | |

¹ Flu seasons span from July 1—June 30 (Q3, Q4, Q1, and Q2). Q1 and Q2 are part of the flu season named after the previous calendar year (e.g., if the Reporting Quarter is Q2 2022, it is considered part of the 2021 flu season).

² Measures will be reported quarterly. The *reporting quarter (RQ)* refers to the last quarter of both the Active Patient Lookback and the Measurement Period (i.e., the most recent quarter of data).

Table 2: Intervention Reporting Time Periods

| Flu Season (Measurement Year) ¹ | Reporting Quarter ² | Active Patient Lookback Period | # of APL Months Included | Measurement Period (Cumulative Quarters) | # of MP Quarters Included |
|--|--------------------------------|--|--------------------------|--|---------------------------|
| 2021 | Q3 2021 | 4/1/2020–9/30/2021 Q2 2020–Q3 2021 | 18 | 7/1/2021–9/30/2021 Q3 2021 | 1 |
| | Q4 2021 | 4/1/2020–12/31/2021 Q2 2020–Q4 2021 | 21 | 7/1/2021–12/31/2021 Q3 2021–Q4 2021 | 2 |
| | Q1 2022 | 4/1/2020–3/31/2022 Q2 2020–Q1 2022 | 24 | 7/1/2021–3/31/2022 Q3 2021–Q1 2022 | 3 |
| | Q2 2022 | 4/1/2020–6/30/2022 Q2 2020–Q2 2022 | 27 | 7/1/2021–6/30/2022 Q3 2021–Q2 2022 | 4 |
| 2022 | Q3 2022 | 4/1/2021–9/30/2022 Q2 2021–Q3 2022 | 18 | 7/1/2022–9/30/2022 Q3 2022 | 1 |
| | Q4 2022 | 4/1/2021–12/31/2022 Q2 2021–Q4 2022 | 21 | 7/1/2022–12/31/2022 Q3 2022–Q4 2022 | 2 |
| | Q1 2023 | 4/1/2021–3/31/2023 Q2 2021–Q1 2023 | 24 | 7/1/2022–3/31/2023 Q3 2022–Q1 2023 | 3 |
| | Q2 2023 | 4/1/2021–6/30/2023 Q2 2021–Q2 2023 | 27 | 7/1/2022–6/30/2023 Q3 2022–Q2 2023 | 4 |
| 2023 | Q3 2023 | 4/1/2022–9/30/2023 Q2 2022–Q3 2023 | 18 | 7/1/2023–9/30/2023 Q3 2023 | 1 |
| | Q4 2023 | 4/1/2022–12/31/2023 Q2 2022–Q4 2023 | 21 | 7/1/2023–12/31/2023 Q3 2023–Q4 2023 | 2 |
| | Q1 2024 | 4/1/2022–3/31/2024 Q2 2022–Q1 2024 | 24 | 7/1/2023–3/31/2024 Q3 2023–Q1 2024 | 3 |
| | Q2 2024 | 4/1/2022–6/30/2024 Q2 2022–Q2 2024 | 27 | 7/1/2023–6/30/2024 Q3 2023–Q2 2024 | 4 |
| 2024 | Q3 2024 | 4/1/2023–9/30/2024 Q2 2023–Q3 2024 | 18 | 7/1/2024–9/30/2024 Q3 2024 | 1 |
| | Q4 2024 | 4/1/2023–12/31/2024 Q2 2023–Q4 2024 | 21 | 7/1/2024–12/31/2024 Q3 2024–Q4 2024 | 2 |
| | Q1 2025 | 4/1/2023–3/31/2025 Q2 2023–Q1 2025 | 24 | 7/1/2024–3/31/2025 Q3 2024–Q1 2025 | 3 |
| | Q2 2025 | 4/1/2023–6/30/2025 Q2 2023–Q2 2025 | 27 | 7/1/2024–6/30/2025 Q3 2024–Q2 2025 | 4 |

¹ Flu seasons span from July 1—June 30 (Q3, Q4, Q1, and Q2). Q1 and Q2 are part of the flu season named after the previous calendar year (e.g., if the Reporting Quarter is Q2 2022, it is considered part of the 2021 flu season).

² Measures will be reported quarterly. The *reporting quarter (RQ)* refers to the last quarter of both the Active Patient Lookback and the Measurement Period (i.e., the most recent quarter of data).

Table 3: Reporting Time Periods and Due Dates

| Flu Season (Measurement Year) ¹ | Reporting Quarter ² | Report Due Date | Blinded Comparative Report Provided |
|--|-----------------------------------|-----------------|--|
| 2021 | Q3 2021 | Feb 15, 2022 | Mar 29, 2022 |
| | Q4 2021 | | |
| | Q1 2022 | Apr 15, 2022 | May 27, 2022 |
| | Q2 2022 | Jul 15, 2022 | Aug 26, 2022 |
| 2022 | Q3 2022 | Oct 14, 2022 | Nov 29, 2022 |
| | Q4 2022 | Jan 17, 2023 | Feb 28, 2023 |
| | Q1 2023 | Apr 14, 2023 | May 26, 2023 |
| | Q2 2023 | Jul 14, 2023 | Aug 25, 2023 |
| 2023 | Q3 2023 | Oct 16, 2023 | Nov 29, 2023 |
| | Q4 2023 | Jan 16, 2024 | Feb 27, 2024 |
| | Q1 2024 | Apr 15, 2024 | May 29, 2024 |
| | Q2 2024 | Jul 15, 2024 | Aug 26, 2024 |
| 2024 | Q3 2024 | Oct 15, 2024 | Nov 26, 2024 |
| | Q4 2024 | Jan 15, 2025 | Feb 26, 2025 |
| | Q1 2025 | Apr 15, 2025 | May 28, 2025 |
| | Q2 2025 | Jul 15, 2025 | Aug 26, 2025 |

3 MEASURE SPECIFICATIONS

3.1 ACTIVE PATIENT POPULATION

Defining the Active Patient Population is the first step of determining each measure's denominator.

Patients are included in the Active Patient Population if they:

1. are age 19–99 on the first day of the Measurement Year (MY) (July 1st), **AND**
2. have completed ≥ 1 ambulatory visit (see [Table 4](#)) in the Active Patient Lookback (APL)^a period with any specialty, **AND**
3. have **EITHER**
 - an Assigned PCP, **OR**
 - ≥ 1 ambulatory visit with a PCP in the APL^{a,b} (see [Table 5](#)).

If Assigned PCP is not a reliable designation at your organization, individual HCOs can elect to only use ≥ 1 visit with a PCP in the APL.

For Organizations that elect to use the Assigned PCP designation, patients meeting EITHER criterion (Assigned PCP OR ≥ 1 visit with a PCP) should be considered eligible for the APL.

Patients are excluded from the Active Patient Population if:


1. there is evidence of hospice or palliative care in the APL (see [Table 6](#)), **OR**
2. the patient died prior to the end of the RQ.

Note: Per NAC recommendations, not all exclusions in the HEDIS® AIS-E measures (e.g., history of immunocompromising conditions) are used in Rise to Immunize™.

^a The APL includes the current Measurement Period (MP).

^b ≥ 1 visit with a PCP in the APL also counts as ≥ 1 ambulatory visit with any specialty in the APL (i.e., ≥ 1 visit with a PCP in the APL satisfies both criteria).

3.1.1 Defining the Active Patient Population



¹The Active Patient Lookback (APL) spans from 15 months prior to each Measurement Year’s first RQ (Q3) and runs through the current RQ (See Tables 1 & 2). **The APL includes the Measurement Period (MP).**

3.1.2 Date of Birth (DOB) Range to Establish Active Patient Population

| Flu Season (Measurement Year) | DOB on or after | DOB on or before |
|-------------------------------|-----------------|------------------|
| 2019 (Q3 2019 – Q2 2020) | 7/2/1919 | 7/1/2000 |
| 2020 (Q3 2020 – Q2 2021) | 7/2/1920 | 7/1/2001 |
| 2021 (Q3 2021 – Q2 2022) | 7/2/1921 | 7/1/2002 |
| 2022 (Q3 2022 – Q2 2023) | 7/2/1922 | 7/1/2003 |
| 2023 (Q3 2023 – Q2 2024) | 7/2/1923 | 7/1/2004 |
| 2024 (Q3 2024 – Q2 2025) | 7/2/1924 | 7/1/2005 |

Table 4: Suggested Codes to Identify Visits

Organizations should use their own definition for classifying ambulatory outpatient activity (face-to-face or telehealth¹), using this list as a guide.

| CPT/HCPCS Codes | Description |
|------------------------------|---|
| 99201–99205, 99211–99215 | Evaluation & Management Office Visit |
| 99241–99245 | Evaluation & Management Office Consultation |
| 99385–99387, 99395–99397 | Evaluation & Management Preventive Visit |
| 99401–99404 | Preventive Medicine: Individual Counseling Visit |
| 99411–99412 | Preventive Medicine: Group Counseling Visit |
| 99420, 99429 | Other Preventive Medicine Services |
| G0402 | Initial Preventive Physical Examination (“Welcome to Medicare” Visit) |
| G0438, G0439 | Medicare Annual Wellness Visit |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient |
| T1015 | Clinic visit/encounter, all inclusive |
| 99421 – 99423, G2061 – G2063 | E-visit (effective 1/1/2020) |
| 99441 – 99444, 98966 – 98969 | Phone E&M |
| G2010, G2012 | Virtual Communication (CMS) |

¹ Telehealth visits can be identified using the codes specified above as e-visit, phone, or virtual communication; or by the presence of a telehealth modifier or a telehealth POS code associated with any of the codes listed in this table.

Table 5: Suggestions for Defining Primary Care and Eligible Providers

| |
|---|
| <p>Primary care should, <u>at minimum</u>, include:</p> <ol style="list-style-type: none"> 1. Family practice 2. General practice 3. Geriatrics 4. Internal medicine 5. Obstetrics/gynecology <p>(Organizations may include <u>additional</u> specialties that they consider to be part of primary care.)</p> |
| <p>Eligible providers <u>may</u> include:</p> <ol style="list-style-type: none"> 1. Doctor of Medicine (MD) 2. Doctor of Osteopathy (DO) 3. Nurse Practitioner (NP) 4. Physician Assistant (PA) 5. Advanced Practice Registered Nurse (APRN) 6. Other Advanced Practice Professionals (APPs) |

Table 6: Suggested Codes for Identifying Hospice/Palliative Care

Organizations should use their own definition for classifying Palliative/Hospice Care, using this list as a guide.

| Codes for Palliative/Hospice Care | |
|-----------------------------------|---|
| ICD-9 | V66.7 |
| ICD-10 | Z51.5 |
| CPT | 99377–99378 |
| HCPCS | G0182, G9473 - G9479 Q5001–Q5010 S0255, S0271, S9126 T2042–T2046 |
| POS (Place of Service) | 34 |

3.2 MEASURE 1 (INFLUENZA)

3.2.1 Denominator


Equivalent to the Active Patient Population (see [Section 3.1](#)).

3.2.2 Numerator

Number of denominator patients who meet any of the following criteria:

- were administered an influenza vaccination (at the HCO or elsewhere) any time during the current Measurement Period up to and including the last day of the Reporting Quarter, **OR**
- had an adverse reaction caused by the influenza vaccine or its components before or during the Measurement Period (see [Table 7](#)).

3.2.3 Measure 1 (Influenza) Flowchart



¹ MP = Measurement Period (See Tables 1 & 2)

3.3 MEASURES 2-4 NUMERATOR PARTS

While the influenza vaccination is administered annually, the vaccination for Td/Tdap is administered once every 10 years and the vaccinations (or vaccination series) for pneumococcal and zoster are administered once in a lifetime (twice for some high-risk patients). Therefore, Measures 2-4 will each contain two Numerator Parts (A and B) to separately account for vaccinations already received and vaccinations being administered during the Campaign. This is so that we can track the overall success of the Rise to Immunize™ Campaign and progress toward our goal of 25 million vaccinations by 2025.

Numerator **Part A** will be used to track the number of vaccines administered (i.e., current care gaps closed) during the campaign. It is a count of patients who received the vaccination (in the case of zoster, completed the series) **during the Measurement Period (MP)**. Patients should not be counted in Part A if a vaccination was newly documented in the MP but was administered prior to the MP. The date of administration takes precedence over the date of documentation.

Numerator **Part B** is a count of patients who received the vaccination **prior to the MP** or ever had an adverse reaction. Patients should be counted in Part B if a vaccination was newly documented in the MP but was administered prior to the MP.

3.4 MEASURE 2 (PNEUMOCOCCAL)

3.4.1 Denominator

Patients from the Active Patient Population (see [Section 3.1](#)) who are *age 66 and older* as of the start of the Measurement Year (July 1).

3.4.2 Numerator Part A


Number of denominator patients who were administered (at the HCO or elsewhere) a pneumococcal vaccination any time during the current Measurement Period, up to and including the last day of the Reporting Quarter.

3.4.3 Numerator Part B

Number of denominator patients who:

- were documented as having received the pneumococcal vaccination prior to the Measurement Period, **OR**
- had an adverse reaction caused by the pneumococcal vaccine or its components before or during the Measurement Period (see [Table 7](#)).

3.4.4 Measure 2 (Pneumococcal) Flowchart



¹ MP = Measurement Period (See Tables [1](#) & [2](#))

3.5 MEASURE 3 (Td/Tdap)

3.5.1 Denominator

Equivalent to the Active Patient Population (see [Section 3.1](#))

3.5.2 Numerator Part A


Number of denominator patients who were administered (at the HCO or elsewhere) a Td or Tdap vaccination any time during the current Measurement Period, up to and including the last day of the Reporting Quarter.

3.5.3 Numerator Part B

Number of denominator patients who:

- were documented as having received a Td or Tdap vaccination in the 9 years prior to the start of the Measurement Period, **OR**
- have a history of at least one of the following contraindications before or during the Measurement Period (see [Table 7](#)):
 - Anaphylaxis due to Tdap vaccine, anaphylaxis due to Td vaccine or its components, **OR**
 - Encephalopathy due to Tdap or Td vaccine.

3.5.4 Measure 3 (Td/Tdap) Flowchart



¹ MP = Measurement Period (See [Tables 1 & 2](#))

3.6 MEASURE 4 (ZOSTER)

3.6.1 Denominator

Patients from the Active Patient Population (see [Section 3.1](#)) who are *age 50 and older* as of the start of the Measurement Year (July 1)

3.6.2 Numerator Part A

Number of denominator patients who (at the HCO or elsewhere) received a **second dose** of the herpes zoster **recombinant**^a vaccine (i.e., completed the vaccination series) any time during the current Measurement Period, up to and including the last day of the Reporting Quarter


*Note: To be compliant for Numerator Part A, patients must also have been administered (at the HCO or elsewhere) a **first dose** of the herpes zoster recombinant vaccine. First doses administered **prior** to the Measurement Period should be counted. Only the second dose is reported in Numerator Part A; the first dose is a requirement of the second, but it is not reported separately.*

3.6.3 Numerator Part B

Number of denominator patients who:

- were documented as having received **two** doses (i.e., one second dose) of the herpes zoster **recombinant** vaccine prior to the Measurement Period, **OR**
- had an adverse reaction caused by the zoster vaccine or its components before or during the Measurement Period (see [Table 7](#)).

3.6.4 Measure 4 (Zoster) Flowchart



¹ MP = Measurement Period (See Tables [1](#) & [2](#))

² Patients must also have been administered (at the HCO or elsewhere) a first dose of the herpes zoster recombinant vaccine.

^a There are two types of zoster vaccinations: recombinant (2 doses) and live (single dose). The live vaccine was discontinued in the U.S. as of November 18th, 2020—it will not be counted in Rise to Immunize™. Patients who received the live vaccination are not compliant for either Numerator Part A or B.

3.7 MEASURE 5 (BUNDLE)

3.7.1 Denominator

Patients from the Active Patient Population (see [Section 3.1](#)) who are *age 66 and older* as of the start of the Measurement Year (July 1).

3.7.2 Numerator

Number of denominator patients who meet requirements for **EITHER** Numerator Part A **OR** Part B of each Measure (1, 2, 3, **AND** 4, i.e., influenza, pneumococcal, Tdap, **AND** zoster vaccinations).

3.7.3 Measure 5 (Bundle) Flowchart




Table 7: Suggested Codes for Identifying Adverse Reactions, Anaphylaxis, and Encephalitis

Organizations should use their own definition for classifying adverse reactions, anaphylaxis, and encephalitis, using this list as a guide.

| Adverse Reaction to: | SNOMEDCT | Mapped ICD-10 Equivalent |
|----------------------|---|--|
| Influenza | 420113004 | T50.B95- |
| Pneumococcal | 293116002 | T50.A95- |
| Td/Tdap | 428281000124107, 428291000124105, 192711008, 192712001, 192710009 | G04.02 T50.A15- T50.A95- T80.52X- |
| Zoster | 451291000124104 | T50.B95- |

4 CHANGE LOG

| Date | Measure(s) Impacted | Change Summary |
|-------|---------------------|---|
| 2021 | | |
| 11/19 | APL | Added a table (p.11) containing the range of eligible Dates of Birth for each Measurement Year. |
| 11/19 | 1-4 | Clarified that <u>ever</u> means <u>before or during the Measurement Year</u> in the adverse reaction exclusions. |

5 QUICK LINKS & CONTACT INFORMATION

[Rise to Immunize™ website](#)
[Reporting Template](#)

Send questions to RiseToImmunize@amga.org.

| Members of the Rise to Immunize™ National Advisory Committee (NAC) | |
|--|---|
| (Emeritus) Randy Bergen, M.D. Kaiser Permanente | Mitchel C. Rothholz, RPh, M.B.A. American Pharmacists Association |
| Francis Colangelo, M.D., FACP, MS-HQS Premier Medical Associates, P.C. | Vincenza Snow, M.D. Pfizer |
| Leon Jerrels, RN, CPHQ Kelsey-Seybold Clinic | Elizabeth Sobczyk, M.S.W., M.P.H. The Gerontological Society of America |
| David Kim, M.D., M.A. U.S. Department of Health and Human Services | Litjen (L.J.) Tan, M.S., Ph.D. Immunization Action Coalition |
| Stanley Martin, M.D. Geisinger | Charles Van Duyne, M.D., M.S. USMD Health System |
| Carrie Regnier, RN, M.P.H. Norton Medical Group | |